INBX
Inhibrx
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 2
Revenue Plunges
EPS Beats Expectation
Revenue Keeps Dropping
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About INBX
Inhibrx Biosciences, Inc.
A biotechnology company committed to researching and developing new biological agents for the treatment of various diseases.
11025 N. Torrey Pines Road, Suite 140 La Jolla, California 92037
--
Inhibrx Biosciences, Inc., was incorporated under the laws of the State of Delaware on January 8, 2024 and is a direct, wholly owned subsidiary of Inhibrx, Inc. The Company is a clinical-stage biopharmaceutical company with a portfolio of novel biotherapeutic drug candidates developed using its proprietary modular protein engineering platform.
Company Financials
EPS
INBX has released its 2024 Q4 earnings. EPS was reported at -3.09, versus the expected -2.88, missing expectations. The chart below visualizes how INBX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
INBX has released its 2024 Q4 earnings report, with revenue of 100.00K, reflecting a YoY change of -93.88%, and net profit of -47.87M, showing a YoY change of 48.86%. The Sankey diagram below clearly presents INBX’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
